Hereditary Diseases Clinical Trial
Official title:
Biomarker for Friedreich's Ataxia: An International, Multicenter, Observational, Longitudinal Protocol
International, multicenter, observational, longitudinal monitoring study to identify biomarker/s for Friedreich's Ataxia and to explore the clinical robustness, specificity, and long-term variability of these biomarker/s
An ataxia is neurological disorder of balance and coordination resulting from dysfunctions of the cerebellum. Friedreich's ataxia (FRDA) is most common ataxia in white population, with an estimated prevalence of 2-4 cases per 100,000 individuals. With an average age of onset of 10-15 years, the disease is characterized by dysarthria, deep sensory loss, hypertrophic cardiomyopathy, spinocerebellar ataxia, pyramidal weakness, diabetes mellitus, and skeletal abnormalities. FRDA is an autosomal recessive disorder caused by pathogenic variant/s in the FXN gene, which encodes the mitochondrial protein frataxin. In 98% of cases these are homozygous guanine-adenine-adenine (GAA) triplet repeat expansions in the first intron of the FXN gene. The remaining cases are compound heterozygotes for a GAA repeat expansion plus a FXN point mutation or deletion. GAA repeat expansions suppress transcription of the FXN gene, leading to frataxin deficiency. Until now there is no FDA-approved therapy for FRDA, but potential agents for treatment are in developing phases. As such, especially antioxidants like idebenone are tested in clinical trials as FRTA medication, whereas another study identified p38 inhibitors as potential therapeutic agents. Various clinical rating scales including the Scale for the Assessment and Rating of Ataxia (SARA), Friedreich's Ataxia Rating Scale (FARS), and the International Cooperative Ataxia Rating Scale (ICARS) have been used as trial endpoints in FRDA, but these measurements have limited sensitivity to disease progression over 12 months. Furthermore, there are no validated, objective central or peripheral nervous system biomarkers of disease progression for use in clinical trials as intermediate endpoints. It is the goal of the BioFridA study to identify, validate, and monitor FRDA biomarker/s. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00001466 -
Study of Clinical and Molecular Manifestations of Genetic Disorders
|
N/A | |
| Active, not recruiting |
NCT04428710 -
Assessment Psychological Distress for Cancer Heredity Test
|
||
| Recruiting |
NCT04531696 -
UZ/KU Leuven Program for Post-mortem Tissue Donation to Enhance Research
|
N/A | |
| Completed |
NCT01343953 -
Cord Blood Transplantation in Severe Aplastic Anemia
|
Phase 2 | |
| Not yet recruiting |
NCT05358964 -
Family Health Histories: Creating a Culturally Tailored Tool to Reduce Health Disparities in the Black Community
|
N/A | |
| Completed |
NCT02416440 -
Durban Diabetes Study:A Study of the Epidemiology of Diabetes Mellitus in Urban South Africans of African Descent (DDS)
|
Phase 0 | |
| Active, not recruiting |
NCT05587439 -
Investigating Hereditary Risk In Thoracic Cancers (INHERIT)
|
||
| Withdrawn |
NCT04531878 -
BSEP Function Rescue During Childhood Inhereditary Cholestatic Diseases
|
Phase 2/Phase 3 | |
| Completed |
NCT02917070 -
Parental Consanguinity and Family History of Kidney Disease in Turkish Kidney Disease Population
|
N/A | |
| Active, not recruiting |
NCT01645904 -
A Social Media Approach to Improve Genetic Risk Communication Phase I
|
||
| Not yet recruiting |
NCT05721326 -
Sequential EHR Based Interventions to Increase Genetic Testing for Breast and Ovarian Cancer Predisposition
|
N/A | |
| Recruiting |
NCT05161169 -
Implementation of Whole Genome Sequencing as Screening in a Diverse Cohort of Healthy Infants
|
N/A | |
| Active, not recruiting |
NCT04528498 -
Embryo Health Study
|
||
| Recruiting |
NCT05453474 -
Cell-based Non-invasive Prenatal Testing as an Alternative to Invasive Chorionic Villus Sampling
|
N/A | |
| Terminated |
NCT00314691 -
Development of New Prenatal Diagnostic Tests From Maternal Blood
|
N/A |